English Polski

Wyszuk. zaawans.

Tom 10, Nr 3 (2017)
Artykuł przeglądowy
Opublikowany online: 2017-10-25

dostęp otwarty

Pokaż PDF Pobierz plik PDF
Wyświetlenia strony 803
Wyświetlenia/pobrania artykułu 3593
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Babeszjoza — nowe wyzwanie w transfuzjologii?

Joanna Szymczak1, Adrian Syta1, Katarzyna Tołkacz1, Małgorzata Bednarska1, Maria Joanna Doligalska1
Journal of Transfusion Medicine 2017;10(3):90-98.

Streszczenie

Zarażenie pierwotniakiem Babesia microti jest przyczyną babeszjozy — choroby człowieka
przenoszonej przez kleszcze. Od niedawna choroba ta pojawia się poza obszarami endemicznymi,
gdzie jedną z przyczyn jej rozprzestrzeniania się są transfuzje krwi i przeszczepy narządów
w warunkach terapeutycznej immunosupresji. W takich okolicznościach utajona choroba
rozwija się w ostrą, zagrażającą życiu postać. Niestety obecnie dostępne leki stosowane przeciw
pierwotniakom malarii nie są skuteczne przeciw piroplazmom. Zapewne wynika to z różnych
strategii rozwoju tych pasożytów w erytrocycie. W celu ustalenia nowych terapii bada się leki,
które hamują podziały pierwotniaków lub uszkadzają ich kwasy nukleinowe. Aby obniżyć
ryzyko przenoszenia pasożytów z rodzaju Babesia z krwią, opracowano technologie inaktywacji
pasożytów, zmniejszające ich żywotność i zakaźność. Choroba z postaci ostrej przechodzi
w przewlekłą, podlegającą nawrotowi, dlatego też istnieje potrzeba zidentyfikowania mechanizmu,
który jest odpowiedzialny za wznowienie babeszjozy po immunoterapii, w której limfocyty
z funkcjami regulacyjnymi odgrywają kluczową rolę.

Słowa kluczowe: Babesia microtitransfuzja krwiwznowienie zarażeniaimmunosupresja

Artykuł dostępny w formacie PDF

Pokaż PDF Pobierz plik PDF

Referencje

  1. Paparini A, Senanayake SN, Ryan UM, et al. Molecular confirmation of the first autochthonous case of human babesiosis in Australia using a novel primer set for the beta-tubulin gene. Exp Parasitol. 2014; 141: 93–97.
    CrossRefPubMed
  2. Hunfeld KP, Hildebrandt A, Gray JS. Babesiosis: recent insights into an ancient disease. Int J Parasitol. 2008; 38(11): 1219–1237.
    CrossRefPubMed
  3. Herwaldt BL, Linden JV, Bosserman E, et al. Transfusion-associated babesiosis in the United States: a description of cases. Ann Intern Med. 2011; 155(8): 509–519.
    CrossRefPubMed
  4. C R. Szczepiorkowski, Z. M. and Dunbar, N. Babesia parasitemia rebound after red blood cell exchange. J Clin Apheresis. ; 2016.
    CrossRef
  5. Homer MJ, Aguilar-Delfin I, Telford SR, et al. Babesiosis. Clinical Microbiology Reviews. 2000; 13(3): 451–469.
    CrossRef
  6. Leiby DA. Transfusion-associated babesiosis: shouldn't we be ticked off? Ann Intern Med. 2011; 155(8): 556–557.
    CrossRefPubMed
  7. Herwaldt BL, McGovern PC, Gerwel MP, et al. Endemic babesiosis in another eastern state: New Jersey. Emerg Infect Dis. 2003; 9(2): 184–188.
    CrossRefPubMed
  8. Holman MS, Caporale DA, Goldberg J, et al. Anaplasma phagocytophilum, Babesia microti, and Borrelia burgdorferi in Ixodes scapularis, southern coastal Maine. Emerg Infect Dis. 2004; 10(4): 744–746.
    CrossRefPubMed
  9. Joseph JT, Roy SS, Shams N, et al. Babesiosis in Lower Hudson Valley, New York, USA. Emerg Infect Dis. 2011; 17(5): 843–847.
    CrossRefPubMed
  10. Weld ED, Eimer KM, Saharia K, et al. Transfusion medicine illustrated. The expanding range and severity of babesiosis. Transfusion. 2010; 50(2): 290–291.
    CrossRefPubMed
  11. Meldrum SC, Birkhead GS, White DJ, et al. Human babesiosis in New York State: an epidemiological description of 136 cases. Clin Infect Dis. 1992; 15(6): 1019–1023.
    PubMed
  12. White DJ, Talarico J, Chang HG, et al. Human babesiosis in New York State: Review of 139 hospitalized cases and analysis of prognostic factors. Arch Intern Med. 1998; 158(19): 2149–2154.
    PubMed
  13. Poisnel E, Ebbo M, Berda-Haddad Y, et al. Babesia microti: an unusual travel-related disease. BMC Infect Dis. 2013; 13: 99.
    CrossRefPubMed
  14. Centers for Disease Control and Prevention (CDC). Babesiosis surveillance - 18 States, 2011. MMWR Morb Mortal Wkly Rep. 2012; 61(27): 505–509.
    PubMed
  15. CDC. National Notifiable Diseases Surveillance System. Available at http://www.cdc.gov/osels/ph_surveillance/nndss/nndsshis.htm. Accessed June. ; 27: 2017.
  16. Vannier E, Krause PJ. Human babesiosis. N Engl J Med. 2012; 366(25): 2397–2407.
    CrossRefPubMed
  17. Gray J, Zintl A, Hildebrandt A, et al. Zoonotic babesiosis: overview of the disease and novel aspects of pathogen identity. Ticks Tick Borne Dis. 2010; 1(1): 3–10.
    CrossRefPubMed
  18. Haapasalo K, Suomalainen P, Sukura A, et al. Fatal babesiosis in man, Finland, 2004. Emerg Infect Dis. 2010; 16(7): 1116–1118.
    CrossRefPubMed
  19. Martinot M, Zadeh MM, Hansmann Y, et al. Babesiosis in immunocompetent patients, Europe. Emerg Infect Dis. 2011; 17(1): 114–116.
    CrossRefPubMed
  20. Zintl A, Mulcahy G, Skerrett HE, et al. Babesia divergens, a bovine blood parasite of veterinary and zoonotic importance. Clin Microbiol Rev. 2003; 16(4): 622–636.
    PubMed
  21. Walter G, Weber GA. study on the transmission (transstadial, transovarial) of Babesia microti, strain „Hannover i, ” in its tick vector, Ixodes ricinus. Tropenmedical Parasitology. ; 1981(32): 228–230.
  22. Gelfand JA, Callahan MV. Babesiosis: An Update on Epidemiology and Treatment. Curr Infect Dis Rep. 2003; 5(1): 53–58.
    PubMed
  23. Hildebrandt A, Hunfeld KP, Baier M, et al. First confirmed autochthonous case of human Babesia microti infection in Europe. Eur J Clin Microbiol Infect Dis. 2007; 26(8): 595–601.
    CrossRefPubMed
  24. Casati S, Sager H, Gern L, et al. Presence of potentially pathogenic Babesia sp. for human in Ixodes ricinus in Switzerland. Ann Agric Environ Med. 2006; 13(1): 65–70.
    PubMed
  25. Gray JS. Babesia sp.: emerging intracellular parasites in Europe. Pol J Microbiol. 2004; 53 Suppl: 55–60.
    PubMed
  26. Gray J, von Stedingk LV, Gürtelschmid M, et al. Transmission studies of Babesia microti in Ixodes ricinus ticks and gerbils. J Clin Microbiol. 2002; 40(4): 1259–1263.
    PubMed
  27. Katargina O, Geller J, Vasilenko V, et al. Detection and characterization of Babesia species in Ixodes ticks in Estonia. Vector Borne Zoonotic Dis. 2011;11(7):923–8.View ArticlePubMedGoogle Scholar.
  28. Siński E, Bajer A, Welc R, et al. Babesia microti: prevalence in wild rodents and Ixodes ricinus ticks from the Mazury Lakes District of North-Eastern Poland. Int J Med Microbiol. 2006; 296 Suppl 40: 137–143.
    CrossRefPubMed
  29. Welc-Falęciak R, Bajer A, Paziewska-Harris A, et al. Diversity of Babesia in Ixodes ricinus ticks in Poland. Adv Med Sci. 2012; 57(2): 364–369.
    CrossRefPubMed
  30. Wójcik-Fatla A, Zając V, Sawczyn A, et al. Prevalence of Babesia microti in Ixodes ricinus ticks from Lublin region (eastern Poland). Ann Agric Environ Med. 2006; 13(2): 319–322.
    PubMed
  31. Skotarczak B, Cichocka A. Isolation and amplification by polymerase chain reaction DNA of Babesia microti and Babesia divergens in ticks in Poland. Ann Agric Environ Med. 2001; 8(2): 187–189.
    PubMed
  32. Asman M, Solarz K, Cuber P, et al. Detection of protozoans Babesia microti and Toxoplasma gondii and their co-existence in ticks (Acari: Ixodida) collected in Tarnogórski district (Upper Silesia, Poland). Ann Agric Environ Med. 2015; 22(1): 80–83.
    CrossRefPubMed
  33. Humiczewska M, Kuźna-Grygiel W. [A case of imported human babesiosis in Poland]. Wiad Parazytol. 1997; 43(2): 227–229.
    PubMed
  34. Moniuszko A, Dunaj J, Swięcicka I, et al. Co-infections with Borrelia species, Anaplasma phagocytophilum and Babesia spp. in patients with tick-borne encephalitis. Eur J Clin Microbiol Infect Dis. 2014; 33(10): 1835–1841.
    CrossRefPubMed
  35. Welc-Falęciak R, Pawełczyk A, Radkowski M, et al. First report of two asymptomatic cases of human infection with Babesia microti (Franca, 1910) in Poland. Ann Agric Environ Med. 2015; 22(1): 51–54.
    CrossRefPubMed
  36. Żukiewicz-Sobczak W, Zwoliński J, Chmielewska-Badora J, et al. Prevalence of antibodies against selected zoonotic agents in forestry workers from eastern and southern Poland. Ann Agric Environ Med. 2014; 21(4): 767–770.
    CrossRefPubMed
  37. Eberhard ML, Walker EM, Steurer FJ. Survival and infectivity of Babesia in blood maintained at 25 C and 2-4 C. J Parasitol. 1995; 81(5): 790–792.
    PubMed
  38. Cursino-Santos JR, Alhassan A, Singh M, et al. Babesia: impact of cold storage on the survival and the viability of parasites in blood bags. Transfusion. 2014; 54(3): 585–591.
    CrossRefPubMed
  39. Wormser GP, Prasad A, Neuhaus E, et al. Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection. Clin Infect Dis. 2010; 50(3): 381–386.
    CrossRefPubMed
  40. Gubernot DM, Nakhasi HL, Mied PA, et al. Transfusion-transmitted babesiosis in the United States: summary of a workshop. Transfusion. 2009; 49(12): 2759–2771.
    CrossRefPubMed
  41. Leiby DA. Babesiosis and blood transfusion: flying under the radar. Vox Sang. 2006; 90(3): 157–165.
    CrossRefPubMed
  42. Johnson ST, Cable RG, Tonnetti L, et al. Seroprevalence of Babesia microti in blood donors from Babesia-endemic areas of the northeastern United States: 2000 through 2007. Transfusion. 2009; 49(12): 2574–2582.
    CrossRefPubMed
  43. Brennan MB, Herwaldt BL, Kazmierczak JJ, et al. Transmission of Babesia microti Parasites by Solid Organ Transplantation. Emerg Infect Dis. 2016; 22(11).
    CrossRefPubMed
  44. Goodell AJ, Bloch EM, Krause PJ, et al. Costs, consequences, and cost-effectiveness of strategies for Babesia microti donor screening of the US blood supply. Transfusion. 2014; 54(9): 2245–2257.
    CrossRefPubMed
  45. Gorenflot A, Moubri K, Precigout E, et al. Human babesiosis. Ann Trop Med Parasitol. 1998; 92(4): 489–501.
    PubMed
  46. Leiby DA, Chung APS, Cable RG, et al. Relationship between tick bites and the seroprevalence of Babesia microti and Anaplasma phagocytophila (previously Ehrlichia sp.) in blood donors. Transfusion. 2002; 42(12): 1585–1591.
    PubMed
  47. Linden JV, Wong SJ, Chu FK, et al. Transfusion-associated transmission of babesiosis in New York State. Transfusion. 2000; 40(3): 285–289.
    PubMed
  48. Popovsky MA, Lindberg LE, Syrek AL, et al. Prevalence of Babesia antibody in a selected blood donor population. Transfusion. 1988; 28(1): 59–61.
    PubMed
  49. Tonnetti L, Thorp AM, Deisting B, et al. Babesia microti seroprevalence in Minnesota blood donors. Transfusion. 2013; 53(8): 1698–1705.
    CrossRefPubMed
  50. Hunfeld KP, Allwinn R, Peters S, et al. Serologic evidence for tick-borne pathogens other than Borrelia burgdorferi (TOBB) in Lyme borreliosis patients from midwestern Germany. Wien Klin Wochenschr. 1998; 110(24): 901–908.
    PubMed
  51. Hunfeld KP, Lambert A, Kampen H, et al. Seroprevalence of Babesia infections in humans exposed to ticks in midwestern Germany. J Clin Microbiol. 2002; 40(7): 2431–2436.
    PubMed
  52. Foppa IM, Krause PJ, Spielman A, et al. Entomologic and serologic evidence of zoonotic transmission of Babesia microti, eastern Switzerland. Emerg Infect Dis. 2002; 8(7): 722–726.
    CrossRefPubMed
  53. Hunfeld KP, Brade V. Zoonotic Babesia: possibly emerging pathogens to be considered for tick-infested humans in Central Europe. Int J Med Microbiol. 2004; 293 Suppl 37: 93–103.
    PubMed
  54. Łętowska M. (red.). Medyczne zasady pobierania krwi, oddzielania jej składników i wydawania, obowiązujące w jednostkach organizacyjnych publicznej służby krwi. Instytut Hematologii i Transfuzjologii, Warszawa 2010.
  55. Lobo CA, Cursino-Santos JR, Alhassan A, et al. Babesia: an emerging infectious threat in transfusion medicine. PLoS Pathog. 2013; 9(7): e1003387.
    CrossRefPubMed
  56. Borggraefe I, Yuan J, Telford SR, et al. Babesia microti primarily invades mature erythrocytes in mice. Infect Immun. 2006; 74(6): 3204–3212.
    CrossRefPubMed
  57. Hemmer RM, Ferrick DA, Conrad PA. Role of T cells and cytokines in fatal and resolving experimental babesiosis: protection in TNFRp55-/- mice infected with the human Babesia WA1 parasite. J Parasitol. 2000; 86(4): 736–742.
    CrossRefPubMed
  58. Okła H, Jasik KP, Słodki J, et al. Hepatic tissue changes in rats due to chronic invasion of Babesia microti. Folia Biol (Krakow). 2014; 62(4): 353–359.
    PubMed
  59. Fang DC, McCullough J. Transfusion-Transmitted Babesia microti. Transfus Med Rev. 2016; 30(3): 132–138.
    CrossRefPubMed
  60. Vannier E, Gewurz BE, Krause PJ. Human babesiosis. Infect Dis Clin North Am. 2008; 22(3): 469–88, viii.
    CrossRefPubMed
  61. Usatii N, Khachatrian A, Stratidis J. Spontaneous splenic rupture due to Babesia microti infection: Case report and review of the literature. IDCases. 2014; 1(4): 63–65.
    CrossRefPubMed
  62. Kuwayama DP, Briones RJ. Spontaneous splenic rupture caused by Babesia microti infection. Clin Infect Dis. 2008; 46(9): e92–e95.
    CrossRefPubMed
  63. Guru PK, O Horo JC, Lehrke HD, et al. Exchange transfusion for babesiosis when, how, and how long? Indian J Crit Care Med. 2016; 20(11): 674–676.
    CrossRefPubMed
  64. Krause PJ, McKay K, Gadbaw J, et al. Tick-Borne Infection Study Group. Increasing health burden of human babesiosis in endemic sites. Am J Trop Med Hyg. 2003; 68(4): 431–436.
    PubMed
  65. Krause PJ, Gewurz BE, Hill D, et al. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis. 2008; 46(3): 370–376.
    CrossRefPubMed
  66. Vyas JM, Telford SR, Robbins GK. Treatment of refractory Babesia microti infection with atovaquone-proguanil in an HIV-infected patient: case report. Clin Infect Dis. 2007; 45(12): 1588–1590.
    CrossRefPubMed
  67. Robinson MW, Hutchinson AT, Dalton JP, et al. Peroxiredoxin: a central player in immune modulation. Parasite Immunol. 2010; 32(5): 305–313.
    CrossRefPubMed
  68. Müller S, Liebau E, Walter RD, et al. Thiol-based redox metabolism of protozoan parasites. Trends Parasitol. 2003; 19(7): 320–328.
    PubMed
  69. Park H, Hong SH, Kim K, et al. Characterizations of individual mouse red blood cells parasitized by Babesia microti using 3-D holographic microscopy. Sci Rep. 2015; 5: 10827.
  70. Rudzinska MA. Ultrastructure of intraerythrocytic Babesia microti with emphasis on the feeding mechanism. J Protozool. 1976; 23(2): 224–233.
    PubMed
  71. Kapishnikov S, Weiner A, Shimoni E, et al. Oriented nucleation of hemozoin at the digestive vacuole membrane in Plasmodium falciparum. Proc Natl Acad Sci U S A. 2012; 109(28): 11188–11193.
    CrossRefPubMed
  72. Massimine KM, McIntosh MT, Doan LT, et al. Eosin B as a novel antimalarial agent for drug-resistant Plasmodium falciparum. Antimicrob Agents Chemother. 2006; 50(9): 3132–3141.
    CrossRefPubMed
  73. Cui L, Su Xz. Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev Anti Infect Ther. 2009; 7(8): 999–1013.
    CrossRefPubMed
  74. Olafson KN, Ketchum MA, Rimer JD, et al. Mechanisms of hematin crystallization and inhibition by the antimalarial drug chloroquine. Proc Natl Acad Sci U S A. 2015; 112(16): 4946–4951.
    CrossRefPubMed
  75. Ehrhardt K, Davioud-Charvet E, Ke H, et al. The antimalarial activities of methylene blue and the 1,4-naphthoquinone 3-[4-(trifluoromethyl)benzyl]-menadione are not due to inhibition of the mitochondrial electron transport chain. Antimicrob Agents Chemother. 2013; 57(5): 2114–2120.
    CrossRefPubMed
  76. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006; 43(9): 1089–1134.
    CrossRefPubMed
  77. Wittner M, Rowin KS, Tanowitz HB, et al. Successful chemotherapy of transfusion babesiosis. Ann Intern Med. 1982; 96(5): 601–604.
    PubMed
  78. Krause PJ, Lepore T, Sikand VK, et al. Atovaquone and azithromycin for the treatment of babesiosis. N Engl J Med. 2000; 343(20): 1454–1458.
    CrossRefPubMed
  79. Pradel G, Schlitzer M. Antibiotics in malaria therapy and their effect on the parasite apicoplast. Curr Mol Med. 2010; 10(3): 335–349.
    PubMed
  80. Andrews NW, Webster P. Phagolysosomal escape by intracellular pathogens. Parasitol Today. 1991; 7(12): 335–340.
    PubMed
  81. Wittner M, Lederman J, Tanowitz HB, et al. Atovaquone in the treatment of Babesia microti infections in hamsters. Am J Trop Med Hyg. 1996; 55(2): 219–222.
    PubMed
  82. Hughes LM, Lanteri CA, O'Neil MT, et al. Design of anti-parasitic and anti-fungal hydroxy-naphthoquinones that are less susceptible to drug resistance. Mol Biochem Parasitol. 2011; 177(1): 12–19.
    CrossRefPubMed
  83. de Souza NB, de Andrade IM, Carneiro PF, et al. Blood shizonticidal activities of phenazines and naphthoquinoidal compounds against Plasmodium falciparum in vitro and in mice malaria studies. Mem Inst Oswaldo Cruz. 2014; 109(5): 546–552.
    PubMed
  84. Schlenke P. Pathogen inactivation technologies for cellular blood components: an update. Transfus Med Hemother. 2014; 41(4): 309–325.
    CrossRefPubMed
  85. Grellier P, Benach J, Labaied M, et al. Photochemical inactivation with amotosalen and long-wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components. Transfusion. 2008; 48(8): 1676–1684.
    CrossRefPubMed
  86. Tonnetti L, Proctor MC, Reddy HL, et al. Evaluation of the Mirasol pathogen [corrected] reduction technology system against Babesia microti in apheresis platelets and plasma. Transfusion. 2010; 50(5): 1019–1027.
    CrossRefPubMed
  87. Rosenberg YJ, Evans CB. Resistance of mice suppressed for IgM production to Babesia microti infection. Nature. 1979; 281(5729): 302–304.
    PubMed
  88. Parrodi F, Jacobson RH, Wright IG, et al. The effect of immune serum and complement on the in vitro phagocytosis of Babesia rodhaini. Parasite Immunol. 1991; 13(5): 457–471.
    PubMed
  89. Chapman WE, Ward PA. Babesia rodhaini: requirement of complement for penetration of human erythrocytes. Science. 1977; 196(4285): 67–70.
    PubMed
  90. Jeong YI, Hong SH, Cho SH, et al. Induction of IL-10-producing CD1dhighCD5+ regulatory B cells following Babesia microti-infection. PLoS One. 2012; 7(10): e46553.
    CrossRefPubMed
  91. Raffalli J, Wormser GP. Persistence of babesiosis for >2 years in a patient on rituximab for rheumatoid arthritis. Diagn Microbiol Infect Dis. 2016; 85(2): 231–232.
    CrossRefPubMed
  92. Igarashi I, Waki S, Ito M, et al. Role of CD4+ T cells in the control of primary infection with Babesia microti in mice. J Protozool Res. 1994; 4: 164–171.
  93. Hardy R. Chapter 7: B Lymphocyte Development and Biology. W: Paul W.E. (red.) Fundamental Immunology. Lippincott Williams & Wilkins, Philadelphia. ; 2008: 237–269.
  94. Vallerskog T, Gunnarsson I, Widhe M, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol. 2007; 122(1): 62–74.
    CrossRefPubMed
  95. Bouaziz JD, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev. 2008; 224: 201–214.
    CrossRefPubMed
  96. Silva JC, Cornillot E, McCracken C, et al. Genome-wide diversity and gene expression profiling of Babesia microti isolates identify polymorphic genes that mediate host-pathogen interactions. Sci Rep. 2016; 6: 35284.
    CrossRefPubMed
  97. Castle SC. Clinical relevance of age-related immune dysfunction. Clin Infect Dis. 2000; 31(2): 578–585.
    CrossRefPubMed

Informacje o plikach cookie

Niezbędne pliki cookie

Zawsze aktywne

Te pliki cookie są niezbędne do prawidłowego wyświetlania i działania strony internetowej. Zablokowanie ich może spowodować nieprawidłowe działanie strony.

Analityczne pliki cookie

W ramach naszej strony internetowej korzystamy z narzędzi analitycznych, takich jak Google Analytics, które umożliwiają nam weryfikację ruchu na stronie internetowej. Narzędzia te mogą wymagać użycia plików cookie.

Społecznościowe pliki cookie

Są to pliki cookie powiązane z portalami społecznościowymi, z których korzystamy. Zaakceptowanie ich pozwoli na powiązanie Twojej wizyty na stronie z naszymi profilami w mediach społecznościowych.

Marketingowe pliki cookie

Są to pliki cookie odpowiedzialne za prowadzenie działań reklamowych i marketingowych - zgoda na ich wykorzystanie pozwoli nam kierować do Ciebie reklamy, bazujące na podstawie Twoich wcześniejszych aktywności w ramach naszej stronie internetowej.

Copyright © 2023-2024 Via Medica Regulamin Polityka cookies Polityka prywatności Nota prawna